About POTE ankyrin domain family member C
POTE ankyrin domain family member C (POTEC) is a protein
from Homo sapiens identified by UniProt accession
B2RU33, 542 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | POTE ankyrin domain family member C |
|---|
| UniProt accession | B2RU33 |
|---|
| Gene | POTEC |
|---|
| Organism | Homo sapiens |
|---|
| Length | 542 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (6)
Diseases linked to this target (Open Targets).
- age at onset · score 0.03
- Myopia · score 0.03
- neoplasm · score 0.00
- breast cancer · score 0.00
- nonpapillary renal cell carcinoma · score 0.00
- cancer · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-B2RU33-F1 | alphafold | PREDICTED | 65.80 | — |
Amino-acid sequence (542 residues)
MVTEVCSMPA ASAVKKPFDL RSKMGKWFHH RFPCCKGSGK SNMGTSGDHD DSFMKMLRSK MGKCCHHCFP CCRGSGTSNV GTSGDHDNSF MKTLRSKMGK WCCHCFPCCR GSGKSNVGAW GDYDDSAFME PRYHVRREDL DKLHRAAWWG KVPRKDLIVM LRDTDMNKRD KQKRTALHLA SANGNSEVVQ LLLDRRCQLN VLDNKKRTAL IKAVQCQEDE CVLMLLEHGA DQNIPDEYGN TTLHYAVHNE DKLMAKALLL YGADIESKNK CGLTPLLLGV HEQKQQVVKF LIKKKANLNA LDRYGRTALI LAVCCGSASI VNLLLEQNVD VSSQDLSGQT AREYAVSSHH HVICELLSDY KEKQMLKISS ENSNPEQDLK LTSEEESQRL KVSENSQPEK MSQEPEINKD CDREVEEEIK KHGSNPVGLP ENLTNGASAG NGDDGLIPQR RSRKPENQQF PDTENEEYHS DEQNDTRKQL SEEQNTGISQ DEILTNKQKQ IEVAEKKMNS ELSLSHKKEE DLLRENSMLQ EEIAMLISGD WN
Explore POTE ankyrin domain family member C with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets